CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole.
作者： Vivekanand Jha , Nirupama Chandel , Pardeep K. Aggarwal , Mukut Minz , Vinay Sakhuja
DOI: 10.1097/FPC.0B013E32832BD085
关键词: CYP3A5 、 Cytochrome P-450 CYP3A 、 Pharmacogenetics 、 Tacrolimus 、 Genotype 、 Cytochrome 、 Biology 、 Enzyme assay 、 Ketoconazole 、 Pharmacology
摘要: ObjectivesKetoconazole retards metabolic degradation of tacrolimus through its effect on the cytochrome P-450 enzyme system and allows reduction in treatment costs. Enzyme activity is determined by a single nucleotide polymorphism (*1/*3) CYP3A5 gene.MethodsWe prospectively investigated i
cabdirect.org
sci-hub.se 参考文章(28)
C. Balram, Qingyu Zhou, Yin Bun Cheung, Edmund J. D. Lee, CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. European Journal of Clinical Pharmacology. ,vol. 59, pp. 123- 126 ,(2003) , 10.1007/S00228-003-0594-2
Özden Hatirnaz, İnci Yildiz, Müge Aydin Sayitoğlu, Uğur Özbek, Common Cytochrome p4503A (CYP3A4 and CYP3A5) and Thiopurine S-Methyl Transferase (TPMT) Polymorphisms In Turkish Population Turkish Journal of Medical Sciences. ,vol. 36, pp. 11- 15 ,(2006)
Khalid Farouk El-Dahshan, Mohamed Adel Bakr, Ahmed Farouk Donia, Ali El-Sayed Badr, Mohamed Abdel-Kader Sobh, Ketoconazole-Tacrolimus Coadministration in Kidney Transplant Recipients: Two-Year Results of a Prospective Randomized Study American Journal of Nephrology. ,vol. 26, pp. 293- 298 ,(2006) , 10.1159/000094133
Mohamed A. Sobh, Ahmed F. Hamdy, Amgad E. El Agroudy, Kefaya El Sayed, Tarek El-Diasty, Mohamed A. Bakr, Mohamed A. Ghoneim, Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: Long-term follow-up and study of metabolic consequences American Journal of Kidney Diseases. ,vol. 37, pp. 510- 517 ,(2001) , 10.1053/AJKD.2001.22075
Yang Dai, Kazunori Iwanaga, Yvonne S. Lin, Mary F. Hebert, Connie L. Davis, Weili Huang, Evan D. Kharasch, Kenneth E. Thummel, In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochemical Pharmacology. ,vol. 68, pp. 1889- 1902 ,(2004) , 10.1016/J.BCP.2004.07.012
T. Gerntholtz, M. D. Pascoe, J. F. Botha, J. Halkett, D. Kahn, The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries. European Journal of Clinical Pharmacology. ,vol. 60, pp. 143- 148 ,(2004) , 10.1007/S00228-004-0745-0
Hector Carbajal, Liliana Soltero, Carlos Rodríguez-Montalvo, Alejandro Valdés, Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience. Transplantation. ,vol. 77, pp. 1038- 1040 ,(2004) , 10.1097/01.TP.0000122343.51904.C3
D R J Kuypers, H de Jonge, M Naesens, E Lerut, K Verbeke, Y Vanrenterghem, CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients Clinical Pharmacology & Therapeutics. ,vol. 82, pp. 711- 725 ,(2007) , 10.1038/SJ.CLPT.6100216
M. ROY FIRST, TIMOTHY J. SCHROEDER, ABIGAIL MICHAEL, SUNDARAM HARIHARAN, PATRICIA WEISKITTEL, J. WESLEY ALEXANDER, Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. Transplantation. ,vol. 55, pp. 1000- 1004 ,(1993) , 10.1097/00007890-199305000-00009
Nina Isoherranen, Shana R. Ludington, Raymond C. Givens, Jatinder K. Lamba, Susan N. Pusek, E. Claire Dees, David K. Blough, Kazunori Iwanaga, Roy L. Hawke, Erin G. Schuetz, Paul B. Watkins, Kenneth E. Thummel, Mary F. Paine, The Influence of CYP3A5 Expression on the Extent of Hepatic CYP3A Inhibition Is Substrate-Dependent: An in Vitro-in Vivo Evaluation Drug Metabolism and Disposition. ,vol. 36, pp. 146- 154 ,(2008) , 10.1124/DMD.107.018382